Public Radio

Seattle doctor’s radical idea saves 70,000 people a year

KUOW 94.9, Nov. 13, 2017

There was a time when the cure for leukemia was almost as lethal as the disease. Before bone marrow transplants, patients were treated with arsenic or radiation — and the outlook was often considered hopeless.

Read More

Cambridge Biotech Company Claims Breakthrough On New Class Of ‘Gene-Silencing’ Drugs

WBUR 90.9 FM, Sept. 22, 2017

Stock in the Cambridge pharmaceutical company, Alnylam, is soaring due to expectations it may have successfully tested a so-called “RNAI” drug that could treat a rare malfunction of the nervous system. Luke Timmerman, who writes the bio-tech newsletter “The Timmerman Report,” joined Morning Edition.

Read More

Is There A Pickup Coming For Biotech IPOs?

WBUR 90.9 FM, July. 10, 2017

It’s been a relatively slow year for the U.S. biotech sector. So far, only 16 companies nationwide have gone public since January.

That’s about half as many as during the boom years between 2013 and 2015.

But the last couple of weeks have seen four IPOs, including two here in Massachusetts, for the firms Mersana and Aileron. Both are focused on cancer drugs.

For a look at the dry spell, and what might be driving the possible shift underway, we spoke to Luke Timmerman, founder and editor of the biotech industry newsletter the Timmerman Report.

Read More

How Leroy Hood changed Seattle’s biotech industry

KUOW 94.9, Nov. 1, 2016

Bill Radke talks to biotech journalist Luke Timmerman about his new book, “Hood: Trailblazer of the Genomics Age.”

Read More

President Of Washington Life Sciences Trade Group Steps Down

KUOW 94.9, Sept. 21, 2015

Jeannie Yandel talks to Luke Timmerman of the Timmerman Report about Chris Rivera’s tenure as President of the Washington Biotechnology And Biomedical Association.

Read More

What Seattle’s Biotech Community Gained When It Lost Amgen

KUOW 94.9, Jul. 31, 2015

Marcie Sillman talks to Luke Timmerman, founder and editor of the Timmerman Report, about Juno Therapeutics and other biotech startups like Just Biotherapeutics that came out of the closure of Amgen’s Seattle offices last year.

Read More

Looking Beyond Federal Funding At Fred Hutch

KUOW 94.9, Apr. 3, 2015

Marcie Sillman talks to Luke Timmerman, of the Timmerman Report, about the Fred Hutchinson’s Cancer Research Center’s efforts to find new ways to bring in revenue for research.

Read More